Kalcoral-K75 mcg+500 mg+1000 IU

Kalcoral-K is a combination nutritional supplement containing vitamin K2 (as menaquinone-7), calcium from a coral source, and vitamin D3. It is indicated for the following uses, classified by strength of evidence:

• Established/guideline-supported use: Prevention and treatment of dietary calcium and vitamin D3 deficiency, and as a supportive/adjunct measure (alongside lifestyle modification and, where indicated, prescription anti-osteoporosis therapy) to help maintain bone mineral density in individuals at risk of osteoporosis, such as postmenopausal women, elderly individuals, and patients on long-term corticosteroid therapy.
• Adjunct use: Adjunctive calcium and vitamin D3 repletion in patients with osteopenia or low bone mass, used under medical supervision together with other recommended measures (weight-bearing exercise, adequate protein intake, fall-prevention).
• Evidence-limited/emerging use: The menaquinone-7 (vitamin K2) component is included for its proposed role in activating osteocalcin and matrix Gla-protein, which is theorized to support bone mineralization and healthy vascular calcium handling. However, clinical evidence for a distinct, independent benefit of menaquinone-7 supplementation on fracture risk reduction or cardiovascular outcomes is still evolving and is not yet conclusive; this should be regarded as a supportive rationale rather than a separately proven indication.

Kalcoral-K is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease on its own; it should be used as directed by a physician.

Each dose (tablet/capsule) of Menaquinone-7 + Coral Calcium + Vitamin D3 typically provides:

• Menaquinone-7 (Vitamin K2) - commonly 45-90 mcg
• Coral Calcium (calcium sourced from fossilized coral, providing elemental calcium, typically as calcium carbonate) - commonly 500-1000 mg elemental calcium
• Vitamin D3 (Cholecalciferol) - commonly 400-1000 IU

Exact strengths vary by manufacturer and formulation. Refer to the product label of the specific marketed brand for its precise composition.

Kalcoral-K is a fixed-dose combination nutritional supplement that brings together three nutrients involved in bone metabolism: menaquinone-7, a long-chain form of vitamin K2; coral-derived calcium, a natural source of elemental calcium; and vitamin D3 (cholecalciferol), which facilitates intestinal calcium absorption.

Vitamin D3 increases absorption of dietary and supplemental calcium from the gut and helps maintain normal serum calcium and phosphate levels. Calcium is the principal mineral of bone and is required for normal bone mineralization, muscle contraction, nerve conduction, and blood clotting. Menaquinone-7 acts as a cofactor that activates vitamin K-dependent proteins (osteocalcin and matrix Gla-protein) proposed to help direct calcium into bone and away from soft tissue, although this specific clinical benefit is still being studied.

Kalcoral-K is used as a combined approach to support bone health when dietary intake of these nutrients is insufficient.

Kalcoral-K belongs to the therapeutic class of Vitamin and Mineral combination supplements - specifically a Vitamin K2 (menaquinone-7) + Calcium + Vitamin D3 combination used for bone health support.

Menaquinone-7 + Coral Calcium + Vitamin D3 combines three agents with complementary roles in calcium and bone metabolism:

• Vitamin D3 (Cholecalciferol): Is hydroxylated in the liver to 25-hydroxyvitamin D and then in the kidney to the active form, 1,25-dihydroxyvitamin D (calcitriol), which increases intestinal absorption of calcium and phosphate, promotes renal calcium reabsorption, and supports normal bone mineralization and remodeling.
• Coral Calcium: Supplies elemental calcium (predominantly as calcium carbonate) that is absorbed in the small intestine (absorption enhanced in the presence of adequate vitamin D) and is used for bone mineralization, and for neuromuscular and cardiac function.
• Menaquinone-7 (Vitamin K2): Acts as an essential cofactor for the gamma-carboxylation (activation) of vitamin K-dependent proteins, including osteocalcin (a bone matrix protein) and matrix Gla-protein (an inhibitor of vascular calcification). Its long side chain gives menaquinone-7 a longer biological half-life than vitamin K1, allowing more sustained tissue activity. The precise magnitude of its independent contribution to clinical bone and cardiovascular outcomes remains an area of ongoing research.

Kalcoral-K is generally taken by mouth, preferably with a meal to enhance absorption of the fat-soluble vitamins (D3 and K2). Swallow the tablet/capsule whole with a glass of water; do not crush or chew unless the product is specifically formulated as a chewable. Take at approximately the same time each day for consistent intake.

Kalcoral-K has the following clinically significant interactions:

• Warfarin and other vitamin K antagonists (VKAs): This is an important interaction to flag. The menaquinone-7 (vitamin K2) component can reduce the anticoagulant efficacy of warfarin and other vitamin K antagonists by promoting activation of clotting factors, potentially lowering INR and reducing anticoagulation control. Concurrent use should be avoided unless specifically directed and closely monitored by the prescribing physician, with more frequent INR monitoring.
• Tetracyclines and fluoroquinolone antibiotics: The calcium component can chelate these antibiotics in the gut, reducing their absorption and efficacy; separate dosing by at least 2-3 hours.
• Bisphosphonates and oral levothyroxine: Calcium can reduce absorption of these drugs; administer bisphosphonates or levothyroxine on an empty stomach, well separated (at least 30-60 minutes for bisphosphonates, 4 hours for levothyroxine) from calcium-containing products.
• Thiazide diuretics: Concurrent use with calcium/vitamin D3 may increase the risk of hypercalcemia due to reduced renal calcium excretion; monitor serum calcium.
• Digoxin: Hypercalcemia arising from excessive calcium/vitamin D intake can increase the risk of digoxin-related cardiac arrhythmia; monitor calcium levels and cardiac status in patients on digoxin.
• Corticosteroids: Can reduce calcium absorption and increase calcium requirement; dose adjustment of calcium/vitamin D may be needed under medical supervision.

Kalcoral-K is generally well tolerated at recommended doses. Reported side effects include:

• Common: Mild gastrointestinal upset, constipation, bloating, flatulence, or nausea (mainly related to the calcium component).
• Uncommon: Headache, dry mouth, mild skin rash (hypersensitivity).
• Rare (usually associated with excessive/prolonged intake beyond recommended dose): Symptoms of hypercalcemia such as loss of appetite, excessive thirst, increased urination, muscle weakness, or confusion (see Overdose).

Kalcoral-K should be used in pregnancy and lactation only if clearly needed and after consulting a physician. Calcium and vitamin D3, at doses within recommended dietary allowances, are commonly used in pregnancy and breastfeeding to meet increased nutrient needs; however, the menaquinone-7 (vitamin K2) component has more limited data specifically in pregnant and lactating women. Total intake from all combined dietary and supplemental sources should not exceed recommended limits, and the potential benefit should be weighed against any potential risk under a physician's guidance before use in these populations.

The following precautions apply to Kalcoral-K:

• Renal impairment: Patients with impaired kidney function have altered calcium, phosphate, and vitamin D handling and are at increased risk of hypercalcemia and vascular/soft-tissue calcification; use with caution and under medical supervision, with periodic monitoring of renal function and serum calcium.
• Avoid exceeding total daily intake: Do not exceed the recommended daily intake of calcium and vitamin D from all combined dietary, fortified-food, and supplemental sources, as cumulative excess intake raises the risk of hypercalcemia and hypervitaminosis D.
• Concurrent anticoagulant therapy: See Interactions - avoid use with warfarin/vitamin K antagonists unless directed and monitored by a physician.
• Hypercalciuria, sarcoidosis, or other granulomatous disease, or history of calcium-containing kidney stones: Use with caution, as these conditions increase susceptibility to hypercalcemia.
• Evidence-limited K2 claims: Marketing claims regarding menaquinone-7's specific benefits for bone strength or cardiovascular/vascular health beyond its role as a vitamin K source are based on evolving evidence and should not be regarded as conclusively established.

Excessive or prolonged intake of Kalcoral-K beyond the recommended dose may lead to hypercalcemia and/or hypervitaminosis D, with symptoms such as nausea, vomiting, constipation, loss of appetite, excessive thirst, frequent urination, muscle weakness, confusion, and, in severe cases, kidney stones, kidney impairment, or cardiac arrhythmia. In case of a suspected overdose, stop the product immediately and seek immediate medical attention or contact a poison control center/emergency services; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Use with caution due to altered calcium/vitamin D handling and increased hypercalcemia risk; see Precautions.

Hepatic impairment: Specific data are limited; vitamin D3 activation partly depends on hepatic hydroxylation, so use with medical guidance in significant hepatic disease.

Elderly: Commonly used in this population for bone health support; monitor renal function and serum calcium periodically, especially with polypharmacy.

Pediatric population: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation section.

Kalcoral-K is typically used as a long-term, ongoing supplement for bone health support, as directed by a physician. Calcium, vitamin D, and vitamin K status should be periodically reassessed (clinically and, where appropriate, with laboratory testing) to confirm continued need and to avoid cumulative excess intake.

Vitamin K2 (Menaquinone-7) + Calcium (coral source) + Vitamin D3 (Cholecalciferol) combination; Bone health / Vitamin-Mineral nutritional supplement

Menaquinone-7 + Coral Calcium + Vitamin D3 acts through three complementary mechanisms: vitamin D3 increases intestinal absorption of calcium and helps maintain normal serum calcium/phosphate levels; coral-derived calcium supplies the elemental calcium substrate required for bone mineralization and other calcium-dependent physiological functions; and menaquinone-7 (vitamin K2) serves as a cofactor for gamma-carboxylation of osteocalcin and matrix Gla-protein, proteins theorized to help direct calcium toward bone matrix and regulate vascular calcium deposition.

The safety and efficacy of Kalcoral-K as a fixed combination have not been established in children. Pediatric calcium and vitamin D3 needs should be determined individually by a physician based on age, weight, dietary intake, and any underlying deficiency, using age-appropriate dosing rather than this adult-oriented combination product. Data on menaquinone-7 supplementation in children are limited, and it should only be used in pediatric patients under specific medical direction.